Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-23
2007-10-23
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S375000, C548S159000, C548S222000
Reexamination Certificate
active
10500888
ABSTRACT:
Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
REFERENCES:
patent: 2004/0132791 (2004-07-01), Surleraux et al.
patent: 2005/0209301 (2005-09-01), Eissenstat et al.
patent: 2005/0261364 (2005-11-01), Wang et al.
patent: 2005/0267074 (2005-12-01), Eissenstat et al.
patent: WO99/67254 (1999-12-01), None
patent: WO 200076961 (2000-12-01), None
Arun K. Ghosh et al., “Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R)-(Hydroxyethylamino) sulfonamide Isostere”, Bioorganic & Medicinal Chemistry Letters, 1998, p. 687-690, vol. 8.
Arun K. Ghosh et al., “Structure Based Design: Novel Spirocyclic Ethers as Nonpeptidal P2-Ligands for HIV Protease Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 1998, pp. 979-982, vol. 8.
Arun K. Ghosh et al., “Structure-based design of non-peptide HIV protease inhibitors”, IL FARMACO, Jan. 2001, pp. 29-32, vol. 56, No. ½.
Kazuhisa Yoshimura et al., “A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003(TMC-126), and Selection of a Novel (A282S) Mutation in the Protease Active Site”, Journal of Virology, Feb. 2002, pp. 1349-1358, vol. 76, No. 3.
Eissenstat Michael
Erickson John W.
Gulnik Sergei
Silva Abelardo
Anderson Rebecca
Barker Michael P.
LandOfFree
Resistance-repellent retroviral protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Resistance-repellent retroviral protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Resistance-repellent retroviral protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3902412